Global Healthcare Opportunities (GHO) has acquired Ardena, a specialist contract development and manufacturing organization (CDMO) focused on early phase drug development, from Mentha Capital.
Ardena is a multi-service CDMO, assisting small-to-mid sized biopharma with services spanning the full development life cycle. The Company offers a “Make, Analyze, File” model from drug substance and drug product manufacturing and bioanalytical services through to regulatory dossier development. Headquartered in Belgium, the company operates across several sites in the Netherlands, Sweden and Latvia.
Ardena caters to a highly diversified base of over 300 customers throughout Europe, the US, Japan and Korea. A high science approach and broad drug development toolkit differentiate Ardena from peers as a comprehensive multi-service pan-European platform.
The GHO team will support management in accelerating Ardena’s plan to enable customers to take a molecule from “target to clinic” with a single outsourced drug development service provider.
“With their deep expertise in the Pharma sector, we are excited now to partner with GHO as we continue our international growth,” Harry Christiaens, CEO of Ardena, said. “Ardena and GHO are fully committed to the science-led approach that delivers valuable solutions for our biopharma customers globally.”
“We are delighted to have the opportunity to work with the Ardena team. Operating within a highly fragmented market, Ardena is the market leading platform from which to build a fully integrated early stage CDMO, serving Biopharma clients globally,” The Partners at GHO Capital, said.